medigraphic.com
Medicina Universitaria

2008, Número 39

<< Anterior Siguiente >>

Med Univer 2008; 10 (39)


Impacto de la biotecnología en la inmunología

Gómez FRA, Tamez GRS, Tamez GP, Rodríguez PC

Idioma: Español
Referencias bibliográficas: 49
Paginas: 92-101
Archivo PDF: 257.13 Kb.


RESUMEN

La biotecnología ha conducido al desarrollo de la inmunología en la generación de pruebas diagnósticas, fármacos y vacunas, útiles en la profilaxia, diagnóstico y tratamiento de una variedad de enfermedades infecciosas y autoinmunitarias y el cáncer. Hoy en día se reconoce que no sólo los investigadores, sino también las principales compañías farmacéuticas internacionales, han comprendido que la terapia tradicional con productos químicos y farmacéuticos está siendo reemplazada por productos derivados de la biotecnología, particularmente la aplicada a la inmunología (conocida como inmunobiotecnología), principalmente por su efectividad en aspectos de salud, pero también debido a que es ecológicamente sustentable y generadora de riqueza comercial.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mason J. Challenges to the economic evaluation of new biotechnological interventions in healthcare. PharmacoEconomics 1999;16:119-25.

  2. Petrov RV. Contribution of immunology to the development of biomedical disciplines. Vestn Ross Akad Med Nauk 1999;74:5-9.

  3. Raychaudhuri S, Rock KL. Fully mobilizing host defense: building better vaccines. Nat Biotechnol 1998;16:1025-31.

  4. Wheeler AP, Bernard GR. Applications of molecular biology and biotechnology: antibody therapy of sepsis. J Crit Care 1996;11:77-94.

  5. Babiuk LA. Broadening the approaches to developing more effective vaccines. Vaccine 1999;17:1587-95.

  6. Guillou PJ. Potential impact of immunobiotechnology on cancer therapy. Br J Surg 1987;74:705-10.

  7. Herlyn D, Birebent B. Advances in cancer vaccine development. Ann Med 1999;31:66-78.

  8. Tamez Guerra R, Gómez Flores R. Utilización de citocinas y liposomas como agentes antibacterianos. Ciencia UANL 1998;1:99-109.

  9. Trebak M, Chong JM, Herlyn D, Speicher DW. Efficient laboratory- scale production of monoclonal antibodies using membrane- based high-density cell culture technology. J Immunol Methods 1999;230:59-70.

  10. Fundación OPTI. Impacto de la biotecnología en los sectores industrial y energético. Informe de prospectiva tecnológica. Madrid: Genoma, Sector Industrial y Energético, 2006;pp:1-67.

  11. Academia Mexicana de Ciencias. Información básica sobre biotecnología. Coordinación de Comunicación y Divulgación, 2008.

  12. Bolívar F. Biotecnología moderna para el desarrollo de México en el siglo XXI. Retos y oportunidades. México: Fondo de Cultura Económica, 2002;pp:1-339.

  13. Gomez-Flores R, Tucker SD, Kansal R, Tamez-Guerra R, Mehta RT. Enhancement of antibacterial activity of clofazimine against Mycobacterium avium-M. intracellulare complex infection induced by IFN-g is mediated by TNF-a. J Antimicrob Chemother 1997a;39:189-97.

  14. Gomez Flores R, Rodriguez Padilla C, Mehta RT, Galan Wong L, Mendoza E, Tamez Guerra R. Nitric oxide and TNF-a production by murine peritoneal macrophages activated with a novel 20- kDa protein isolated from Bacillus thuringiensis var. thuringiensis parasporal bodies. J Immunol 1997b;158:3796-9.

  15. Gomez Flores R, Weber RJ. Inhibition of IL-2 production and down regulation of IL-2 and transferrin receptors on rat splenic lymphocytes following PAG morphine administration: a role in NK and T cell suppression. J Interferon Cytokine Res 1999;19:625-30.

  16. Gomez Flores R, Jin Liang S, Weber RJ. Suppression of splenic macrophage functions after acute morphine action in the rat mesencephalon periaqueductal gray. Brain Behav Immun 1999;13:212-24.

  17. Fári MG, Kralovánszky UP. The founding father of biotechnology: Károly (Karl) Ereky. Int J Hort Sci 2006;12:9-12.

  18. Fumento M. Bioevolution. How biotechnlogy is changing our world. San Francisco: Encounter Books, 2003;pp:1-532.

  19. Cohen SN, Chang AC, Boyer HW, Helling RB. Construction of biologically functional bacterial plasmids in vitro. Biotechnology 1992;24:188-92.

  20. Lossing AG, Hatswell EM, Wright JG, Hu Z, MacLeod R. Diagnostic test studies: biotechnology assessment. Surgery 1996;120:1-6.

  21. Barinaga MA. Personal technology transfer effort in DNA. Science 1994;266:1317-8.

  22. Belgrader P, Bennett W, Hadley D, Richards J, et al. Detection of bacteria in seven minutes. Science 1999;284:449-50.

  23. Avallone HL, Beatrice MG, Sze TT. Food and Drug Administration inspection and licensing of manufacturing facilities. Drug Biotechnology Regulation. Bioprocess Technol 1991;315-40. 24. Ada G. Overview of vaccines. Mol Biotechnol 1997;8:123-34.

  24. Lu S, Wang S, Grimes Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008;7:175-91.

  25. Ramírez Pfeiffer C, Díaz Aparicio E, Gomez Flores R, Rodríguez Padilla C, et al. A rapid, simple and specific fluorescence polarization assay to diagnose goat brucellosis using the Brucella melitensis native hapten. Clin Vaccine Immunol 2008;[Epub ahead of print].

  26. Ramirez Pfeiffer C, Nielsen K, Marin Ricalde F, Rodríguez Padilla C, Gomez Flores R. Comparison of fluorescence polarization assay with card and complement fixation tests for the diagnosis of goat brucellosis in a high-prevalence area. Vet Immunol Immunopathol 2006;110:121-7.

  27. Hendriksen CF, de Leeuw WA. In vivo and in vitro production of monoclonal antibodies: current possibilities and future perspectives. Res Immunol 1998;149:611-20.

  28. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-8.

  29. Reichert JM. Monoclonal antibodies in the clinic. Nat Biotechnol 2001;19:819-22.

  30. Kirkpatrick HC. Transfer Factor. J. Allergy Clin Immunol 1998;81:803-13.

  31. Kirkpatrick CH, McDermott MJ, Eisenberg SP. Characterization of transfer factors and methods of use. United States Patent No. 5,883,224, 1999.

  32. Lawrence HS, Borkowsky W. A new basis for the inmunoregulatory activities of transfer factor-An arcane dialect in the lenguage of cells. Cell Immunol 1983;82:102-16.

  33. Borkowsky W, Lawrence HS. Effects of human leucocyte dialysates containing transfer factor in the direct leucocite migration inhibition (LMI) assay. J Immunol 1979;123:1741-7.

  34. Viza D, Phillips J, Rosenfield F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphok Res 1985;4:1.

  35. Akashi K, Shigenori T, Yasuto O, Hideo Y, Masayoshi T. Clinical use of leukocyte dialysate (transfer factor) in Osaka area of Japan. In: Kirkpatrick CH, Burger DR, Lawrence HS, editors. Immunobiology of Transference Factor. New York: Academic Press, 1983;pp:279-91.

  36. Shapiro M. In vivo mass production of insect virus for use as pesticides. In: Kurstak E, editor. Microbial and viral pesticides. New York: Dekker, 1982;pp:463-93.

  37. Behle RW, Tamez Guerra P. Sistemas de producción de baculovirus del tipo poliedro nucleares. En: Galán-Wong LJ, Elías-Santos M, Tamez-Guerra P, Quintero-Ramírez R, Quintero- Zapata I, editores. Procesos biotecnológicos. Monterrey: Publicaciones UANL, 2003;pp:86-108.

  38. Shuler ML, Cho T, Wickham T, et al. Bioreactor development for production of viral pesticides or heterologous proteins in insect cell cultures. Ann NY Acad Sci 1990;589:399-422.

  39. Iatrou K, Farrell PJ, Hashimoto Y. Use of BVACs (BaculoVirus artificial chromosomes) to produce recombinant proteins. US Patent 6,090,584, 2000.

  40. Summers MD. Methods for producing a recombinant baculovirus expression system. US Patent 4,745,051, 1988.

  41. Luckow VA, Summers MD. Trends in the development of baculovirus expression vectors. Bio/Technology 1988;6:47-55.

  42. Cox MMJ. Commercial production in insect cells: One company’s perspective. BioProcess Int 2004:1-5.

  43. Dus-Santos MJ, Wigdorovitz A. Expresión de antígenos del virus de la fiebre aftosa en plantas transgénicas. Rev Sci Tech 2005;24:17587.

  44. Fan H, Pan Y, Fang L, Wong D, et al. Construction and immunogenicity of recombinant pseudotype baculovirus expressing the capsid protein of porcine circovirus type 2 in mice. J Virol Methods 2008;150(1-2):21-26.

  45. Li S, Song KS, Koh SS, Kikuchi A, Lisanti MP. Baculovirus-based expression of mammalian caveolin in sf21 insect cells: A model system for the biochemical and morphological study of caveolae biogenesis. Biochem Mol Biol Int 1996;271:28647-54.

  46. Chang S, Kramer K, Gosnell W, Nishimura T. Baculovirus produced Plasmodium falciparum vaccine. US Patent 7,285,274, 2007.

  47. Gellin B. The Jordan Report 98: Accelerated development of vaccines. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases. EU: National Institutes of Health, 1998;pp:95-113.

  48. Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 2005;23:567-75.

  49. He Q, Manopo I, Lu L, Leung B, et al. Novel immune-fluorescence assay using recombinant nucleocapsid-spike fusion protein as antigen to detect antibodies against severe acute respiratory syndrome coronaviridae. Clin Diag Lab Immunol 2005;12:321-8.




2020     |     www.medigraphic.com